Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer

Breast Cancer Research and Treatment
Kyeongmee ParkKyoung-Mee Kim

Abstract

Topoisomerase II-alpha (TOP2A) has been investigated as a potential predictor for the response to doxorubicin-based chemotherapy which is a representative TOP2A inhibitor and one of the most effective chemotherapeutics for the breast cancer treatment. We performed the assay for the TOP2A gene amplification and deletion on a tissue microarray (TMA) of 284 breast tumor samples from the patients treated by doxorubicin-based adjuvant chemotherapy. TOP2A gene was deleted in six patients (2.1%), whereas TOP2A gene was amplified in 20 (7.1%) of 284 tumors. Twenty-four of 26 TOP2A amplifications and deletions were associated with HER2 co-amplification. TOP2A amplification or deletion was not associated with poor clinical outcome. Nine (34.6%) of 26 patients with TOP2A amplification or deletion had recurrent disease. Thirty percent of the patients with TOP2A amplification had systemic recurrence whereas 50% of the patients with TOP2A deletion had systemic recurrence. On multivariate analysis, histologic grade and tumor size were the significant predictors for the disease-free survival and histologic grade was an only significant predictor for the overall survival. Our study indicates that response to the doxorubicin-based chemotherapy m...Continue Reading

References

Apr 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·A V GudkovI B Roninson
Sep 1, 1999·Genes, Chromosomes & Cancer·T A JärvinenJ Isola
Jan 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M ZambettiL Gianni
Jun 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M J PiccartJ M Nogaret
Mar 12, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·K ParkS Han
Sep 19, 2003·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Kyeongmee ParkJung Young Lee
Nov 25, 2003·Cytopathology : Official Journal of the British Society for Clinical Cytology·A M BofinB M Hagmar
Mar 23, 2004·Genes, Chromosomes & Cancer·Kris K JacobsonJohn S Coon

❮ Previous
Next ❯

Citations

Jan 30, 2007·Breast Cancer Research and Treatment·Edurne ArriolaJorge S Reis-Filho
Oct 2, 2009·Breast Cancer Research and Treatment·Sumanta K PalMark Pegram
Nov 16, 2011·Breast Cancer Research and Treatment·Zsuzsanna VargaHolger Moch
Mar 20, 2012·Pathology Oncology Research : POR·Anna ZaczekJacek Jassem
Sep 10, 2008·Nature Clinical Practice. Oncology·Phuong DinhMartine J Piccart-Gebhart
Apr 30, 2009·Journal of the National Cancer Institute·Dennis J Slamon, Michael F Press
Oct 2, 2007·Current Opinion in Oncology·Isabelle Vanden BemptChristiane De Wolf-Peeters
Aug 9, 2012·The Oncologist·Anna J ZaczekJacek Jassem
Apr 8, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Jiang-Hua QiaoZhen-Zhen Liu
Oct 31, 2009·Pharmacology & Therapeutics·Emanuel RaschiFabrizio De Ponti
Jul 21, 2007·Human Pathology·Maryou B K LambrosJorge S Reis-Filho
Dec 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael F PressDennis J Slamon
Mar 12, 2008·Laboratory Investigation; a Journal of Technical Methods and Pathology·Edurne ArriolaJorge S Reis-Filho
Nov 15, 2007·The Journal of Clinical Endocrinology and Metabolism·Jehad AbubakerKhawla S Al-Kuraya

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

© 2021 Meta ULC. All rights reserved